Exagen Inc. XGN Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Exagen Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s deferred tax assets, valuation allowance?
- Exagen Inc. (XGN) reported deferred tax assets, valuation allowance of $49.21M in Q4 2025.
- How has Exagen Inc.'s deferred tax assets, valuation allowance changed year-over-year?
- Exagen Inc.'s deferred tax assets, valuation allowance increased by 8.8% year-over-year, from $45.24M to $49.21M.
- What is the long-term trend for Exagen Inc.'s deferred tax assets, valuation allowance?
- Over 5 years (2020 to 2025), Exagen Inc.'s deferred tax assets, valuation allowance has grown at a 19.0% compound annual growth rate (CAGR), from $20.6M to $49.21M.